Stay updated on NUC-7738 in Advanced Solid Tumours: Clinical Trial
Sign up to get notified when there's something new on the NUC-7738 in Advanced Solid Tumours: Clinical Trial page.

Latest updates to the NUC-7738 in Advanced Solid Tumours: Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.4.3 has been added to the plan, replacing the previous v3.4.2.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.0 to v3.4.2 on the page.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page now displays a 'Last Update Posted' field and the '(Estimated)' label has been removed, changing how updates are labeled but not altering substantive trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedAdded Phase II melanoma cohort eligibility expansion for NUC-7738 + pembrolizumab: metastatic cutaneous melanoma patients with measurable disease who progressed on up to two prior lines, with at least one PD-1/PD-L1-containing regimen. The progression-in-last-12-months constraint was removed, and the record shows Revision: v3.3.4 with Last Update Posted 2026-01-12.SummaryDifference0.7%

- Check96 days agoChange DetectedFooter now displays Revision: v3.3.3, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 have been removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to NUC-7738 in Advanced Solid Tumours: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NUC-7738 in Advanced Solid Tumours: Clinical Trial page.